These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21340042)

  • 41. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
    Stratton CW; Brown SD
    Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cefditoren, a new aminothiazolyl cephalosporin.
    Balbisi EA
    Pharmacotherapy; 2002 Oct; 22(10):1278-93. PubMed ID: 12389878
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spotlight on cefditoren pivoxil in bacterial infections.
    Wellington K; Curran MP
    Treat Respir Med; 2005; 4(2):149-52. PubMed ID: 15813670
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
    Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
    J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
    Sun H; Chen L; Chen X; Jia X; Li N; Liu W; Tong H; Xiang R; Zhang F; Zhao H; Zhang J; Xu Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jan; 39(1):30-7. PubMed ID: 26792053
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Efficacy and safety of cefditoren pivoxil in treatment of respiratory infections, a clinical study].
    Li JT; Gao L; Xue F; Hao FL; Wang Q; Cai BQ; Gan CL; Liu YN; Yu BX; He LX; Hu BJ; Chen XH; Zheng JC; Yu YS; Lu FF; Liang DR; Cai YN; Kang J; Kong LF; Xiao ZL; Zheng JP; Liu J; Yang WX; Zhou J
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):391-4. PubMed ID: 12820915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).
    Mendes C; Marin ME; Quiñones F; Sifuentes-Osornio J; Siller CC; Castanheira M; Zoccoli CM; López H; Súcari A; Rossi F; Angulo GB; Segura AJ; Starling C; Mimica I; Felmingham D
    Braz J Infect Dis; 2003 Feb; 7(1):44-61. PubMed ID: 12807691
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Bacteriological, pharmacokinetic and clinical studies of cefditoren pivoxil in the pediatric field].
    Toyonaga Y; Ishihara T; Sano T; Tezuka T; Nakamura H
    Jpn J Antibiot; 1993 Jul; 46(7):604-28. PubMed ID: 8371496
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activity of cefditoren against respiratory pathogens.
    Clark CL; Nagai K; Dewasse BE; Pankuch GA; Ednie LM; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2002 Jul; 50(1):33-41. PubMed ID: 12096004
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections.
    Wellington K; Curran MP
    Drugs; 2004; 64(22):2597-618. PubMed ID: 15516158
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
    Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Resistance study of community respiratory pathogens isolated in China from 2005 to 2007].
    Sun HL; Yang QW; Xu YC; Wang H; Xie XL; Chen MJ; Zhang XZ; Liu Y; Ye HF; Sun ZY; Duan Q; Ni YX; Yu YS; Zhao WS; He L; Wang J; Ji P; Liu PP; Zhang LX
    Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2983-7. PubMed ID: 20137709
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Update on the clinical utility and optimal use of cefditoren.
    Barberán J; Aguilar L; Giménez MJ
    Int J Gen Med; 2012; 5():455-64. PubMed ID: 22675264
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical and bacteriological effects of cefetamet pivoxil against community-acquired respiratory tract infections].
    Shimada J; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S; Deguchi K
    Jpn J Antibiot; 1995 Jul; 48(7):949-59. PubMed ID: 7563588
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media.
    Fenoll A; Aguilar L; Robledo O; Giménez MJ; Tarragó D; Granizo JJ; Gimeno M; Coronel P
    J Antimicrob Chemother; 2007 Aug; 60(2):323-7. PubMed ID: 17562681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Antimicrobial activities of cefetamet against clinically isolated strains from community acquired respiratory tract infections. Part III].
    Matsumoto Y; Ishihara R; Suzuki Y; Nishinari C; Ishii Y; Nakane Y; Endo H
    Jpn J Antibiot; 1999 Jun; 52(6):469-77. PubMed ID: 10481811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cefditoren pivoxil: A new oral cephalosporin for skin, soft tissue and respiratory tract infections].
    Hernández-Martin J; Romá E; Salavert M; Doménech L; Poveda JL
    Rev Esp Quimioter; 2006 Sep; 19(3):231-46. PubMed ID: 17099791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.